Knowledge Hub
The success of PRAISE-U is dependent on clear and transparent communication of results. Here you can analyze the data yourself.
Data
Here you can look through the data collected from the project. This is free, public access data collected from the PRAISE-U pilot sites. Click on the map or button below.
Fact Sheets
Downloadable quick references detailing national health system backgrounds, local screening practices, the state of play and recommendations.
Publications
The PRAISE-U consortium is committed to the free access of its findings. As such, all publications related to the project can be reviewed and shared to promote full understanding of the project and the sharing of important data between stakeholders.
About PRAISE-U
In direct partnership with a network of consortium members, PRAISE-U works to encourage early detection and diagnosis of prostate cancer through customised and risk-based screening programmes.
UROWebinars
The new UROwebinar series “Prostate Cancer Screening: PRAISE U training toolbox” is organised by the European School of Urology, the EAU Policy Office, and the PRAISE-U Consortium.
UROWebinar: The Role of MRI in Prostate Cancer Screening and Diagnosis
This e-course explores the role of MRI in prostate cancer (PCa) screening and diagnosis, focusing on recent clinical trials such as Gothenburg and TRANSFORM. The experts discuss how MRI-guided screening is transforming early detection, biopsy rates, and diagnostic accuracy.
This e-course also highlights debates on the applicability of trial findings to broader populations, as well as the potential impact on real-world screening protocols and patient outcomes.
Additionally, the e-course examines the implications for radiologists and urologists, which includes the feasibility of MRI-first screening and its integration into clinical practice across Europe.
UROWebinar: The History of Prostate Cancer Screening trials: Lessons from ERSPC, PLCO and CAP
This e-course explores how decades of research have shaped current understanding and practice in early prostate cancer detection. The discussion traces the evolution of PSA testing and examines landmark screening trials, including ERSPC, PLCO, Göteborg, and CAP, which have provided critical insights into mortality reduction, overdiagnosis, and the balance of benefits and harms in screening.
The session highlights how evidence from both randomized trials and real-world practice is guiding Europe toward more organized, population-based screening. With new initiatives such as PRAISE-U and the EU Cancer Screening Programme, the conversation focuses on the future of prostate cancer screening in Europe—aiming to ensure early detection, reduce mortality, and deliver equitable care for men across all member states.
UROWebinar: The role of risk stratification of prostate cancer
This is the third episode of the new series “Prostate Cancer Screening: PRAISE U training toolbox” organised by the European School of Urology, the EAU Policy Office, and the PRAISE-U Consortium. This recording introduction will provide a recap of the previous episodes.
The recording examines the emerging role of risk stratification in prostate cancer (PCa) screening, highlighting how predictive models and biomarkers are reshaping screening strategies and clinical decision-making. The experts will discuss how various factors (e.g., PSA levels, MRI findings, genetic markers, clinical data, etc.) are integrated into risk models to refine screening recommendations.
A presentation will also cover long-term risk assessment and the impact of age, family history, and PSA thresholds on screening protocols. Additionally, the recording will explore the growing role of genetic testing in PCa risk prediction, including the significance of BRCA1/2 mutations, Lynch syndrome, and other genetic risk calculators. The presenters will discuss how genetic information is incorporated into predictive models and its implications for personalised screening and treatment. The recording will also address the challenges and benefits of integrating genetic testing into clinical practice, as well as future advancements in PCa risk assessment.